NEW YORK (GenomeWeb News) – Transgenomic said on Monday that it has finalized an agreement with Power3 Medical Products giving it rights to Power3's neurodegenerative biomarkers.
The exclusive license gives Transgenomic the rights to certain biomarkers including the NuroPro, a proposed Alzheimer's and Parkinson's diagnostic based on Power3 Medical's proteomics platform, in the US and in certain international markets. Under the agreement, Transgenomic said it will pay Power3 Medical an up-front license fee, milestone payments, royalties, and it will provide development funding and other resources.
Transgenomic will offer the test through its CLIA-certified lab, through which it also offers molecular diagnostic tests for mitochondrial disorders, oncology, hematology, molecular pathology, and inherited disorders.
NuroPro monitors the concentration of a panel of blood serum protein biomarkers and assigns a probability score to reflect the chance that a patient may have a neurodegenerative disease. Doctors can use it to help distinguish patients with Alzheimer's, Parkinson's, or Lou Gehrig's diseases from healthy patients or those with other neurological diseases.
Power3 Medical currently is conducting prospective clinical validation studies of NuroPro in Alzheimer's and Parkinson's diseases, with results indicating sensitivities and specificities of 85 percent to 95 percent for both disorders.